TY - JOUR
T1 - Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam)
T2 - An international, randomized, open-label trial
AU - Hassanein, Mohamed M.
AU - Sahay, Rakesh
AU - Hafidh, Khadija
AU - Djaballah, Khier
AU - Li, Haoyu
AU - Azar, Sami
AU - Shehadeh, Naim
AU - Hanif, Wasim
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/4
Y1 - 2019/4
N2 - Aims: Adding lixisenatide to basal insulin (BI) instead of sulfonylurea (SU), versus continuing SU + BI was assessed in people with type 2 diabetes mellitus (T2DM) who intended to fast during Ramadan 2017. Methods: LixiRam (NCT02941367) was a phase 4, randomized, open-label, 12–22-week study in people with T2DM insufficiently controlled with SU + BI ± 1 oral anti-diabetic. Endpoints included the percentage of participants with ≥1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; primary endpoint) and any hypoglycemia during Ramadan fasting. Results: A numerically lower percentage of participants with lixisenatide + BI (3.3%, 3/91) versus SU + BI (8.9%, 8/90) had ≥1 documented symptomatic hypoglycemia event (intent-to-treat visit 4) during Ramadan fasting (OR: 0.34; 95% CI 0.09, 1.35; proportion difference −0.06, 95% CI −0.13, 0.01); the difference was statistically significant for the ‘any hypoglycemia’ category (lixisenatide + BI: 4.3%, 4/92; SU + BI: 17.4%, 16/92; OR: 0.22; 95% CI 0.07, 0.68; proportion difference −0.13, 95% CI −0.22, −0.04; intent-to-treat). No new treatment-emergent adverse events occurred. Conclusions: Compared with SU + BI, lixisenatide + BI provided lower rates of any hypoglycemia in people with T2DM during Ramadan fasting. Lixisenatide + BI therapy may be a suitable treatment option during fasting.
AB - Aims: Adding lixisenatide to basal insulin (BI) instead of sulfonylurea (SU), versus continuing SU + BI was assessed in people with type 2 diabetes mellitus (T2DM) who intended to fast during Ramadan 2017. Methods: LixiRam (NCT02941367) was a phase 4, randomized, open-label, 12–22-week study in people with T2DM insufficiently controlled with SU + BI ± 1 oral anti-diabetic. Endpoints included the percentage of participants with ≥1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; primary endpoint) and any hypoglycemia during Ramadan fasting. Results: A numerically lower percentage of participants with lixisenatide + BI (3.3%, 3/91) versus SU + BI (8.9%, 8/90) had ≥1 documented symptomatic hypoglycemia event (intent-to-treat visit 4) during Ramadan fasting (OR: 0.34; 95% CI 0.09, 1.35; proportion difference −0.06, 95% CI −0.13, 0.01); the difference was statistically significant for the ‘any hypoglycemia’ category (lixisenatide + BI: 4.3%, 4/92; SU + BI: 17.4%, 16/92; OR: 0.22; 95% CI 0.07, 0.68; proportion difference −0.13, 95% CI −0.22, −0.04; intent-to-treat). No new treatment-emergent adverse events occurred. Conclusions: Compared with SU + BI, lixisenatide + BI provided lower rates of any hypoglycemia in people with T2DM during Ramadan fasting. Lixisenatide + BI therapy may be a suitable treatment option during fasting.
KW - Basal insulin
KW - Hypoglycemia
KW - Lixisenatide
KW - Ramadan
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85062326925&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2019.01.035
DO - 10.1016/j.diabres.2019.01.035
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30772385
AN - SCOPUS:85062326925
SN - 0168-8227
VL - 150
SP - 331
EP - 341
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
ER -